Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer.


Journal

Oncology reports
ISSN: 1791-2431
Titre abrégé: Oncol Rep
Pays: Greece
ID NLM: 9422756

Informations de publication

Date de publication:
May 2019
Historique:
received: 12 10 2018
accepted: 26 02 2019
pubmed: 14 3 2019
medline: 25 6 2019
entrez: 14 3 2019
Statut: ppublish

Résumé

Cisplatin (CDDP)‑based combination chemotherapy is the standard for muscle‑invasive bladder cancer (MIBC). However, nearly all patients undergoing CDDP chemotherapy become refractory due to the development of CDDP resistance. Therefore, clarification of the mechanisms of CDDP resistance is urgently needed. The transcribed ultraconserved regions (T‑UCRs) are a novel class of non‑coding RNAs that are highly conserved across species and are associated with carcinogenesis and cancer progression. In addition, emerging evidence has shown the involvement of androgen receptor (AR) signals in urothelial carcinoma (UC) progression. The aim of the present study was to investigate the expression of transcribed ultraconserved region Uc.63+, and to analyze the effects of Uc.63+ on AR expression and CDDP resistance in UC. Quantitative reverse transcription‑polymerase chain reaction (qRT‑PCR) revealed that the expression of Uc.63+ was higher in UC tissues than that in non‑neoplastic bladder tissues and 15 types of normal tissue. An MTT assay revealed that Uc.63+ was involved in cell proliferation. Western blotting demonstrated that the expression of AR was disrupted by the overexpression or knockdown of Uc.63+ in AR‑positive UMUC3 cells. Furthermore, knockdown of Uc.63+ increased sensitivity to CDDP in UMUC3 cells. Conversely, overexpression of Uc.63+ had no effect on CDDP sensitivity in AR‑negative RT112 cells. Additionally, we observed that the expression of Uc.63+ was increased in CDDP‑resistant UMUC3 cells (UMUC3‑CR) in comparison with that in parental UMUC3 cells. Knockdown of Uc.63+ re‑sensitized the UMUC3‑CR cells to CDDP. These results indicated that Uc.63+ may be a promising therapeutic target to overcome CDDP resistance in UC.

Identifiants

pubmed: 30864720
doi: 10.3892/or.2019.7039
doi:

Substances chimiques

AR protein, human 0
Antineoplastic Agents 0
RNA, Untranslated 0
Receptors, Androgen 0
Cisplatin Q20Q21Q62J

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3111-3118

Auteurs

Yohei Sekino (Y)

Department of Molecular Pathology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima 734‑8551, Japan.

Naoya Sakamoto (N)

Department of Molecular Pathology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima 734‑8551, Japan.

Akira Ishikawa (A)

Department of Molecular Pathology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima 734‑8551, Japan.

Ririno Honma (R)

Department of Molecular Pathology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima 734‑8551, Japan.

Yoshinori Shigematsu (Y)

Department of Molecular Pathology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima 734‑8551, Japan.

Tetsutaro Hayashi (T)

Department of Urology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima 734‑8551, Japan.

Kazuhiro Sentani (K)

Department of Molecular Pathology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima 734‑8551, Japan.

Naohide Oue (N)

Department of Molecular Pathology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima 734‑8551, Japan.

Jun Teishima (J)

Department of Urology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima 734‑8551, Japan.

Akio Matsubara (A)

Department of Urology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima 734‑8551, Japan.

Wataru Yasui (W)

Department of Molecular Pathology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima 734‑8551, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH